Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond

Karlyn A. Martin*, Michael J. Cuttica

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication in pulmonary embolism (PE) survivors, characterized by chronic vascular occlusion and pulmonary hypertension. The identification and diagnosis of CTEPH requires a stepwise approach, starting with symptom evaluation, functional evaluation, screening imaging, and progressing to interventional hemodynamic assessment. On the backbone of anticoagulation, CTEPH management necessitates a multidisciplinary approach. Surgical pulmonary thromboendarterectomy (PTE) is the only potentially curative option. In nonoperable disease or residual disease after PTE, interventional balloon pulmonary angioplasty and/or pulmonary-vasodilator therapies can be offered, in collaboration with interventional and vascular pulmonary colleagues. As it is a disease that can cause high morbidity and mortality, CTEPH requires a high index of suspicion to diagnose and treat in patients following PE.

Original languageEnglish (US)
Pages (from-to)478-484
Number of pages7
JournalHematology (United States)
Volume2021
Issue number1
DOIs
StatePublished - Dec 10 2021

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond'. Together they form a unique fingerprint.

Cite this